Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
  • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
  • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
  • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
  • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
  • A61K47/6939—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being a polysaccharide, e.g. starch, chitosan, chitin, cellulose or pectin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents

Definitions

• the present invention relates to the use of microspheres for binding Helicobacter pylori before and after adhesion to the gastric mucosa and/or gastric mucous layer.
• H. pylori a gram-negative bacterium
• H. pylori a gram-negative bacterium
• chronic infection by H. pylori has been associated with increased risk for development of gastritis, peptic ulcer and gastric cancer [2, 3, 4]. Accordingly, H. pylori is classified as a class I carcinogen by the International Agency for Research on Cancer (IARC) [5]. Gastric cancer is the second leading cause of cancer-related deaths in the world [6]. The adhesion of H.
• adhesins bacterial surface-bound proteins
• the mucus layer formed by high-molecular-weight and heavily glycosylated glycoproteins known as mucins, protects gastric epithelial cells against chemical, enzymatic, microbial and mechanical damage.
• Carbohydrate structures expressed on the surface of epithelial cells and mucins serve as main specific ligands for H. pylori adhesins. The carbohydrate structures specific for H.
• pylori also referred as glycosylated receptors, glycan receptors or Gly-Rs
• Lewis B Lewis B
• Fuca2Galp3[Fuca4]GlcNAc-R Fuca2Galp3[Fuca4]GlcNAc-R
• ⁇ type 1 Fuca2Galp3GlcNAc- R
• Sialyl-Lewis X Sialyl-Lewis X
• sLeX NeuAca3Galp4[Fuca3]GlcNAc-R
• Sialyl-Lewis A NeAca3Gaip3[Fuca4]GlcNAc-R
• H. pylori adhesion is a crucial step for gastric mucosa colonization and establishment of infection since it provides protection from clearance mechanisms.
• infection with strains that express BabA is associated with increased risk for development of duodenal ulcer, intestinal metaplasia and gastric adenocarcinoma [9, 10].
• the LeB glycan structure is naturally expressed on the gastric mucosa of secretor and Lewis-positive individuals which constitute the majority of the human population. Using an animal model that is knock out for an enzyme essential for LeB and H-type 1 antigens biosynthesis, an impairment of BabA- dependent adhesion of H.
• H. pylori Persistent gastric mucosa colonization by H. pylori results in inflammation that is accompanied by de novo expression of sialylated glycans, including sLeX. It has been demonstrated that H. pylori is able to induce the expression of a host glycosyltransferase that leads to sLeX overexpression by the host cells and therefore increases bacterial capacity to adhere to epithelial cells [12].
• H. pylori eradication treatment relies on a triple therapy approach that combines at least two antibiotics and one proton pump inhibitor [13,14]. However, this treatment raises concern due to possible recurrence of infection, high costs, side effects, poor compliance to therapy and, most importantly, the increasing acquired resistance to some antibiotics [15]. In fact, it has been estimated that eradication therapy is unsuccessful in nearly one in every five patients [16]. In addition, H. pylori vaccines are not established yet. WO 2008/105740 describes the preparation of antibodies against the H. pylori BabA adhesin and suggests their application in the development of H. pylori passive vaccination.
• Chitosan has been used for drug encapsulation and gastric delivery due to its gastric retentive capacity [19, 20] and because it is a Food and Drug Administration (FDA) approved polymer [21].
• Chitosan is a natural, biodegradable and non-toxic cationic polysaccharide obtained by N-deacetylation of chitin.
• the gastric mucoadhesive properties of chitosan result from electrostatic interactions between its positively charged free amines and gastric mucins, which are negatively charged at the acidic stomach pH.
• chitosan is known for its bacteriostatic properties.
• chitosan Due to electrostatic interactions of chitosan cationic amino groups with anions on the bacterial wall, chitosan has an intrinsic antibacterial activity, inhibiting bacterial proliferation [22].
• the utilization of genipin as crosslinking agent for chitosan microspheres has been previously described [23, 24].
• the present invention provides a microsphere for H. pylori binding, wherein the microsphere comprises receptors for H. pylori, wherein the microspheres and the receptors can bind H. pylori.
• These microspheres are used as a scavenging system, to remove H. pylori from the stomach of infected patients and not for a local drug delivery system. It has been found that the microspheres of the invention can bind H. pylori bacteria. When administered into the stomach, the microspheres can bind H. pylori bacteria which are present on the gastric mucosa and/or gastric mucus layer. This removes the H. pylori bacteria from the gastric mucosa and mucus layer.
• H. pylori bacteria which are contained in the stomach but which are not adhered to the gastric mucosa or mucus layer can also be bound by the microspheres. This prevents the H. pylori bacteria from adhering to the gastric mucosa or mucus layer.
• the result of these effects is that H. pylori bacteria can be removed from the stomach. This reduces colonisation of the gastric mucosa and mucus layer by H. pylori bacteria and reduces or prevents re-colonisation.
• the microspheres with the bound H. pylori bacteria pass out of the stomach, after gastric mucus layer turnover, into the duodenum and are eventually excreted from the body, thereby removing the H.
• H. pylori bacteria from the body.
• H. pylori bacteria By reducing, eliminating and/or preventing colonisation of the gastric mucosa and gastric cells by H. pylori bacteria, the risk of developing conditions associated with H. pylori infection can be reduced. For example, the risk of developing gastritis, peptic ulcer and gastric cancer can be reduced.
• the microsphere can be made up of any suitable material which allows the microsphere to maintain its form at the range of pHs present in gastric and intestinal organs, i.e. between about 1.2 and about 9.
• the material should be such that the microsphere does not disintegrate at the range of pHs present in gastric and intestinal organs.
• the material is preferably a polymeric material. Suitable polymeric materials that could be used to make the microsphere include chitosan, polygalactosamine, polylysine, diethylaminoethyldextran (DEAE), DEAE- imine, etc.
• the microsphere itself (not including the receptors for H. pylori) should also be able to bind to H. pylori.
• the material from which the microsphere is made and, therefore, the microsphere itself has mucoadhesive properties so that it binds gastric cells and mucins. This helps to increase the retention time of the microsphere in the stomach.
• the microsphere and the material from which it is made also binds to bacteria. This may be unspecific binding. Both of these types of bioadhesion can occur due to electrostatic forces. Therefore, the microsphere and the material from which it is made is positively charged so that it binds to the negative charges on the surface of bacteria, mucins and cells.
• the material used to make the microspheres may be a bioadhesive cationic polymer.
• Suitable materials include chitosan, polygalactosamine, polylysine, diethylaminoethyldextran (DEAE), DEAE-imine, etc.
• Polystyrene is not a suitable material so the microsphere should not be made from polystyrene.
• the microsphere is preferably a chitosan microsphere.
• the microsphere is made up of chitosan molecules.
• Chitosan has advantageous bioadhesive properties.
• Chitosan is prepared by the deacetylation of chitin.
• the degree of deacetylation of chitosan should be preferably greater than 80%.
• the chitosan molecular weight should be preferably greater than 100,000 Da.
• the material which forms the microspheres may be modified to attach chemical and biological compounds for a desired purpose. This is in addition to the receptors for H. pylori. However, the attachment of these compounds should not modify the microspheres stability at the range of pHs present in gastric and intestinal organs.
• the microsphere is preferably crosslinked.
• the material forming the microsphere is preferably crosslinked. This helps to ensure that the microsphere is stable, retains its three dimensional structure and does not dissolve.
• a microsphere is stable if it does not disintegrate in simulated gastric fluid (SGF) with pepsin at a pH of 1.2.
• SGF simulated gastric fluid
• the degree of crosslinking is preferably at the minimum level necessary to avoid microsphere disintegration in simulated gastric fluid, particularly in acidic conditions, for example, at a pH of about 1.2.
• the crosslinking of the microsphere should not affect its required properties to allow it to be used to bind H. pylori.
• the microsphere is partially crosslinked.
• the chitosan molecules may be partially crosslinked rather than fully crosslinked.
• Complete crosslinking of chitosan microspheres can reduce the bioadhesive properties of the chitosan microsphere as the amine groups which are involved in bioadhesion can also be used to crosslink the chitosan. If the majority or all the amine groups are used for crosslinking, very few, if any, of the amine groups will remain to provide the advantageous bioadhesive properties.
• the degree of crosslinking to ensure that the microsphere is stable, but also that it retains its advantageous properties can be determined by one skilled in the art.
• crosslinked is intended to include various stages of crosslinking and includes partial crosslinking.
• the important aspect is that the microsphere is crosslinked to a sufficient degree to ensure that the microsphere is stable.
• the microsphere can be crosslinked with any suitable crosslinking agent.
• suitable crosslinking agents include glutaraldehyde, glyoxal, epichlorohydrin, succinaldehyde and genipin.
• the crosslinking agent that is used is genipin due to its low toxicity. Genipin and the other crosslinking agents mentioned above are particularly suitable for crosslinking chitosan.
• a suitable concentration of crosslinking agent and an appropriate length of time for the crosslinking reaction can easily be determined to provide the desired amount of crosslinking.
• the microsphere is a chitosan microsphere which has been crosslinked with genipin.
• partial crosslinking can be achieved, for example, by using lOmM of genipin for between 30 min and 90 min.
• ImM of genipin can be used for between 1 hr and 6 hr.
• the microsphere should have a structure which allows it to bind H. pylori bacteria.
• the microsphere may have a porous structure. This means that the bacteria can be contained in the interior of the microsphere as well as on the surface in order to increase the maximum number of H. pylori bacteria that can be contained in/on the microsphere.
• Microspheres used in this invention are microparticles were the longest measurable diameter is less than or equal to two times longer than the shortest measurable diameter.
• the microsphere should have a size which allows it to effectively bind H. pylori bacteria.
• the microsphere may have a diameter of between about 10 ⁇ and about 1000 ⁇ . Microspheres with these diameters have been shown to give good retention in the stomach.
• the microsphere may have a diameter of between about 10 ⁇ and about 750 ⁇ , or between about 10 ⁇ and about 500 ⁇ .
• a number of microspheres will be used.
• a mixture of sizes may be used.
• the mean diameter may be between about 10 ⁇ and about 1000 ⁇ at a pH of about 7.4.
• the mean diameter may be between about 10 ⁇ and about 750 ⁇ , or between about 10 ⁇ and about 500 ⁇ .
• the mean diameter of the microspheres may be between about 10 ⁇ and about 1000 ⁇ in simulated gastric fluid at a pH of about 1.2.
• the mean diameter may be between about 10 ⁇ and about 750 ⁇ , or between about 10 ⁇ and about 500 ⁇ in simulated gastric fluid at a pH of about 1.2.
• the microsphere comprises receptors for H. pylori. These are receptors which can bind to H. pylori bacteria. More specifically, these receptors bind to molecules which are displayed on the surface of H. pylori bacteria. This allows the microspheres to bind to the H. pylori bacteria, thereby adsorbing and/or absorbing them so that they can be removed from the gastric mucosa and/or mucus layer or prevented from binding to the gastric mucosa and/or mucus layer.
• the receptors can be throughout the microsphere and not just on the surface.
• the receptors can be any suitable receptors which are able to bind to the surface of the H. pylori bacterium.
• the receptors should be specific for the H. pylori bacterium so that the receptors do not bind to other molecules.
• the receptors may be antibodies which can bind to H. pylori bacteria.
• the glycan receptors bind to adhesins on the surface of the H. pylori bacterium. Adhesins are bacterial surface components that facilitate bacterial adhesion, in particular, to the gastric mucosa and/or mucus layer in the case of H. pylori.
• the receptors are glycan receptors specific for H. pylori. These can also be called glycosylated receptors or Gly-R.
• Glycan receptors bind to adhesins on the surface of the H. pylori bacterium.
• the glycan receptors of H. pylori include fucosylated ABO blood group antigens, glycans with charged groups such as sialic acid or sulfate, and glycans which expose fucose, sialic acid, GlcNac and Gal.
• the blood group antigen-binding adhesin (Bab A) binds the Lewis b (Fuca2Galp3[Fuca4]GlcNAc-R) and H type 1 (Fuca2Gaip3GlcNAc-R) histo-blood group carbohydrate structures.
• sialic-acid binding adhesin mediates binding to carbohydrate structures such as Sialyl-Lewis X (NeuAca3Galp4[Fuca3]GlcNAc-R) and Sialyl-Lewis A (NeuAca3Galp3[Fuca4]GlcNAc-R).
• Further glycan receptors include Lewis A, Lewis Y, Lewis X, B-type and A-type receptors.
• Particular glycan receptors that can be used in the invention include: Lewis B (LeB) and H type 1 which are recognized by the blood group antigen-binding adhesin (BabA); and Sialyl- Lewis X (sLeX) and Sialyl-Lewis A (sLeA) which are ligands for the sialic acid binding adhesin (SabA).
• the glycan receptors may be selected from Lewis B and Sialyl-Lewis X receptors.
• the microsphere may comprise a single type of receptor.
• the microsphere may only comprise Lewis B (LeB) receptors or Sialyl-Lewis X (sLeX) receptors.
• the microspheres may comprise a plurality of receptor types.
• the microsphere may comprise Lewis B (LeB) receptors and Sialyl-Lewis X (sLeX) receptors.
• the receptors may be attached to the microspheres in any suitable way so that the receptors can bind to H. pylori bacteria.
• the receptors are preferably attached to the chitosan via the primary alcohol group rather than the more reactive primary amine group. This preserves the primary amine groups of chitosan unchanged since these groups are responsible for chitosan' s mucoadhesive properties. An example of this can be seen in Figure 1.
• Microspheres have been used previously to deliver active ingredients to the stomach.
• Current H. pylori treatment relies on a triple therapy approach that combines at least two antibiotics and one proton pump inhibitor.
• the microsphere of the invention may further comprise an active pharmaceutical ingredient for the treatment or prevention of H. pylori infection.
• the microsphere may comprise an antibiotic against H. pylori or other drugs with antimicrobial activity such as amoxicillin, clarithromycin, metronidazole, ampicillin, tetracycline, doxycycline, oxytetracycline, bismuth, etc.
• the microsphere may comprise more than one antibiotic.
• the microsphere may comprise a proton pump inhibitor such as omeprazole, lansoprazole, rabeprazole, esomeprazole, cimetidine, etc.
• the microspheres may comprise one or more antibiotics and a proton pump inhibitor.
• the microsphere comprises a sub-therapeutic level of an active pharmaceutical ingredient for the treatment or prevention of H. pylori infection.
• the microsphere does not contain an active pharmaceutical ingredient for the treatment or prevention of H. pylori infection.
• the microsphere may contain no active pharmaceutical ingredient whatsoever.
• the microsphere may be in a lyophilised form, i.e. it is a lyophilised microsphere. It has been found that lyophilised microspheres retain their three dimensional structure and their H. pylori binding characteristics.
• a pharmaceutical composition comprising microspheres as described above and optionally one or more pharmaceutically acceptable excipients.
• Suitable pharmaceutically acceptable excipients are well known to those skilled in the art.
• a microsphere as described above for use in binding H. pylori bacteria there is provided a microsphere as described above for use in treating or preventing H. pylori infection, in particular, of the gastric mucosa and/or mucus layer.
• a microsphere as described above in the manufacture of a medicament for binding H. pylori bacteria. Further, there is provided the use of a microsphere as described above in the manufacture of a medicament for treating or preventing H. pylori infection, in particular, of the gastric mucosa and/or mucus layer.
• a method of treating or preventing H. pylori infection of the gastric mucosa and/or mucus layer comprising administering an effective amount of the microspheres described above to a patient.
• treating H. pylori infection means the level of infection is reduced. In other words, the total number of H. pylori bacteria is reduced. Although it is preferred that all H. pylori bacteria should be removed/eliminated from the gastric mucosa and/or mucus layer, in reality this may not be possible. Therefore, the term treating is intended to have a broader meaning of reducing infection and not just eliminating infection.
• the microspheres are administered orally so that the microspheres are delivered to the stomach of the patient.
• the microspheres may be contained in a capsule (e.g. a gelatin capsule) which can dissolve in the stomach to release the microspheres.
• the patient is human.
• the patient has H. pylori colonisation of the gastric mucosa and/or mucus layer.
• the microspheres can be a mixture of different microspheres. For example, some may have one receptor and others may have a different receptor.
• a method of manufacturing a microsphere for binding H. pylori comprising:
• the microsphere is preferably a chitosan microsphere.
• the method may further comprise the step of crosslinking the microsphere.
• the crosslinking is carried out with genipin, especially when the microsphere is a chitosan microsphere.
• the receptors are glycan receptors specific for H. pylori such as Lewis B and/or Sialyl-Lewis X receptors.
• the receptors are preferably attached to the chitosan via the primary alcohol group.
• the method does not involve the step of inserting an active pharmaceutical ingredient into the microsphere.
• the method may further comprise the step of lyophilising the microsphere.
• kits for forming microspheres for binding H. pylori comprising a material for forming microspheres and receptors for H. pylori.
• the kit may further comprise a crosslinking agent.
• microspheres which have bioadhesive properties can be used on their own to bind H. pylori bacteria in a non-specific way. This is thought to be through electrostatic interactions. Therefore, receptors for H. pylori attached to the microspheres are not essential. Therefore, there is provided a method of treating or preventing H. pylori infection of the gastric mucosa and/or mucus layer, the method comprising administering an effective amount of microspheres to a patient, wherein the microspheres can bind H. pylori.
• microsphere comprising receptors are equally applicable to this aspect except for the fact that the receptors for H. pylori are not required.
• the microspheres can be made up of any suitable material, preferably polymeric material, which can maintain microspheres intact at the range of pHs present in human gastrointestinal tract (the stomach and intestine) and which can bind to H. pylori bacteria.
• the material should be able to avoid microspheres degradation at a pH of between about 1.2 and about 9.
• the material used to make the microspheres may be a bioadhesive cationic polymer. Suitable materials include chitosan, polygalactosamine, polylysine, diethylaminoethyldextran (DEAE), DEAE-imine, etc.
• the microspheres are preferably chitosan microspheres. In other words, the microspheres are made up of chitosan molecules.
• the material which forms the microspheres may be modified to attach functional groups for a desired purpose. Modified material should still be able to maintain microspheres without disintegration at the range of pHs present in human gastrointestinal tract and bind H. pylori.
• the microspheres are preferably crosslinked as described above in detail.
• the microspheres are crosslinked with genipin as described in detail above.
• the microspheres preferably comprise a sub-therapeutic level of an active pharmaceutical ingredient for the treatment or prevention of H. pylori infection.
• the microspheres do not contain an active pharmaceutical ingredient for the treatment or prevention of H. pylori infection.
• the microspheres may contain no active pharmaceutical ingredient whatsoever.
• the microspheres may be lyophilised microspheres.
• treating H. pylori infection means the level of infection is reduced. In other words, the total number of H. pylori bacteria is reduced.
• the microspheres are administered orally.
• the patient is human.
• the patient has H. pylori colonisation of the gastric mucosa and/or gastric cells.
• the present invention provides a pharmaceutical composition for treating or preventing H. pylori infection, the composition comprising microspheres which can bind H. pylori and optionally one or more pharmaceutically acceptable excipients.
• the present invention also provides a pharmaceutical composition for treating or preventing H. pylori infection, the composition consisting of microspheres which can bind H. pylori and optionally one or more pharmaceutically acceptable excipients.
• microspheres with receptors can be used in combination with microspheres without receptors.
• composition for treating or preventing H. pylori infection, the composition comprising:
• microspheres which can bind H. pylori
• microspheres comprising receptors for H. pylori that can bind ⁇ . pylori.
• a method of treating or preventing H. pylori infection of the gastric mucosa and/or mucus layer comprising administering an effective amount of the above composition comprising microspheres with and without receptors to a patient.
• composition comprising microspheres with and without receptors for use in treating or preventing H. pylori infection of the gastric mucosa and/or mucus layer.
• the above composition comprising microspheres with and without receptors in the manufacture of a medicament for treating or preventing H. pylori infection of the gastric mucosa and/or mucus layer.
• the microspheres comprising receptors for H. pylori can be a mixture of different microspheres, for example, some having one receptor and others having a different receptor.
• Figure 1 shows a scheme for the chemical immobilization of glycan receptors (GlyRs) on chitosan microspheres: (a) Protection of chitosan reactive primary amine groups with phthalic anhydride; (b) Chitosan O-alkynylation; (c) Immobilization of N3-GlyR using the azide- alkyne conjugation "click reaction”; (d) Deprotection of chitosan primary amine groups.
• GlyRs glycan receptors
• 17.1 strain that express BabA (specific for LeB antigens), binds strongly and in a non-specific way to Ch-Microspheres, strongly and specifically to LeB-Microspheres and in small amounts to Alkyl- or sLeX- Microspheres.
• Figure 3. Chitosan microsphere image obtained by scanning electron microscopy (scale bar 100 ⁇ ).
• Figure 4 Fluorescence kinetic of chitosan microspheres in the presence of 1 mM and 10 mM genipin.
• Chitosan Microspheres to Bind H. pylori and to Prevent/Remove Adhesion of H. pylori to the Gastric Mucosa and Mucus Layer
• the present invention uses a different strategy to avoid and remove H. pylori gastric colonization. It exploits the bioadhesive properties of chitosan to create three dimensional porous microspheres that can be used to bind H. pylori before and after bacterial binding to gastric mucosa and mucus layer.
• chitosan microspheres have already been described as a good vehicle for gastric drug delivery (WO 98/52547), they have never been described as being used to impair H.
• chitosan microspheres can bind different strains of H. pylori and prevent H. pylori from adhering to the gastric cells.
• the inventors have also found that chitosan microspheres can bind to H. pylori which are already adhered to the gastric cells, thereby removing the H. pylori from the gastric cells.
• the inventors studied the effect of chitosan microspheres crosslinked with genipin in preventing/removing H. pylori gastric cell adhesion, under different pH conditions.
• Chitosan microspheres were produced in a high voltage electrostatic system by extruding chitosan droplets (1% w/v in acetic acid) into a 5% w/v sodium triphosphate pentabasic (TPP) solution. Chitosan microspheres were crosslinked in lmM or lOmM genipin solutions (in PBS 0.01M) over different reaction times at 25°C and 120rpm.
• Microsphere size and morphology was visualized by scanning electron microscopy (SEM) and optical microscopy.
• Genipin crosslinking kinetics was assessed with a time lapse using a fluorescence microscope (FM), since genipin fluoresces dark blue when crosslinked, and its chemical structural changes were monitored by Fourier transform infrared (FT-IR) spectroscopy.
• Microspheres stability and swelling in simulated gastric fluid (SGF) with pepsin was evaluated for 7 days by optical microscopy.
• Mucoadhesiveness of microspheres were determined by measuring the capacity of the microspheres to bind porcine stomach mucin type III (M1778, Sigma). Quantification of the adsorbed mucins onto chitosan microspheres was performed applying a colorimetric Periodic Acid-Schiff (PAS) Kit (395B, Sigma).
• PAS Periodic Acid-Schiff
• Bacteria were cultured in microaerophily at 37 °C on trypticase soy agar with 5% sheep blood for 48h and afterwards on pylori gelose for 48h.
• bacteria were labelled with radioactive sulphur (S-35), for visualization, bacteria were labelled with fluorescein isothiocyanate (FITC).
• S-35 radioactive sulphur
• FITC fluorescein isothiocyanate
• a gastric carcinoma cell line MKN45 (mainly expressing sLeX, which binds SabA) was used.
• Cells were grown in RPMI 1640 with glutamax, supplemented with 10% inactivated (30 min, 56°C) fetal bovine serum, lOU/ml penicillin and 10 ⁇ g/ml streptomycin at 37°C in a humidified 5% C0 2 atmosphere.
• MKN45 cells were incubated for 2h with [35S]-H. pylori (Cells+H. pylori); in the second condition, MKN45 cells were incubated for 2h with [35S]-H. pylori, rinsed with buffer to remove non-adherent bacteria and afterwards incubated with chitosan microspheres for another 2h (Cells+H. pylori +Mic); and finally, in the third condition, MKN45 cells were incubated for 2h with chitosan microspheres and afterwards incubated with [35S]-H.
• Genipin crosslinking kinetics revealed that microspheres with lOmM and ImM of genipin are completely crosslinked after 2hr and 7hr, respectively ( Figure 4)
• Genipin crosslinking occurs through the amine groups that are also necessary for maintaining chitosan mucoadhesion. Therefore, optimal crosslinking time and concentration of genipin was determined taking into account that full crosslinking is not desirable, only the minimum to avoid microsphere disintegration in acidic conditions.
• FT-IR of microspheres with lOmM genipin showed a decrease of the characteristic peaks of the amine groups of chitosan at 3375 and 1598 cm "1 with the increase of genipin crosslinking time, meaning that the amine groups are being replaced by amide binding from genipin reaction that appears at 1655 cm-1.
• the increase of the absorption band at 1420 cm "1 with increase of genipin crosslinking time was assigned to the N-H stretching of amide band and ring stretching of genipin molecule (region at 1500-1300 cm-1) [26].
• Microspheres crosslinked with lOmM of genipin for lhr were stable for seven days in simulated gastric fluid (SGF) and were used in all bacteria adhesion tests.
• the mucoadhesiveness of chitosan microspheres decreased with increase of crosslinking time from 0.053+0.008 (0.5 hour) to 0.048+0.008 mg of mucins per mg of microspheres (2 hour).
• Microspheres crosslinked with lOmM of genipin for lhr proved to be stable under acidic conditions for at least 7 days. These microspheres are able to bind H. pylori regardless of bacteria adhesin expression and of the pH. Furthermore, they were able to both remove H. pylori adherent to gastric cells (50-76%) and prevent H. pylori from adhering to gastric cells (47-56%).
• microspheres should be porous and should not degrade so that they are removed intact from the stomach (through the intestinal tract) after gastric mucosal turnover.
• microspheres should be stable in the range of pHs present in gastric and intestinal organs. In order to avoid dissolution of the microspheres in acidic pH, they were crosslinked with genipin. Genipin crosslinking of the microspheres was optimized to maintain its three dimensional structure in acidic conditions without losing the mucoadhesive properties.
• Chitosan microspheres were produced, crosslinked and lyophilized. The degree of crosslinking, size and porosity controls chitosan degradation in the gastric acidic conditions and bacteria binding. Crosslinking enables the microspheres to be removed through the gastrointestinal tract without dissolving.
• Chitosan microspheres bind bacteria, namely H. pylori, in a range of pHs (2.6-7.4) when bacteria are in solution or adherent to cells. These microspheres were also able to prevent bacteria adhesion to gastric cells.
• Chitosan microspheres, crosslinked with genipin and lyophilized, can be used for gastric applications to bind H. pylori and remove it through the gastrointestinal tract.
• Chitosan microspheres, crosslinked with genipin and lyophilized can be decorated with receptors for bacteria to increase its binding specificity.
• the crosslinked chitosan microspheres can be used for the prevention or treatment of H. pylori infection and associated diseases, and the prevention of H. pylori re-infection on antibiotic treated patients.
• mucoadhesive chitosan microspheres were used which had an additional chemical modification.
• the microspheres are decorated with glycosylated receptors (GlyRs) with affinity to H. pylori adhesins, to compete with gastric mucins and attract, bind and remove H. pylori from the stomach.
• GlyRs glycosylated receptors
• H. pylori expressing the Bab A adhesin bind specifically to chitosan microspheres (GlyR-Mic) decorated with LeB.
• Crosslinked chitosan microspheres can attract and bind H. pylori, but unlike the GlyR-Mic that are H. pylori adhesin specific, they bind in a non-specific way.
• the presence of GlyRs on chitosan microspheres improves the attraction and binding of H. pylori since the GlyRs can compete directly with host glycans expressed on mucins and cell surfaces for H. pylori adhesins.
• a combination of chitosan microspheres with different GlyRs can be used in order to improve the biding of H. pylori that express different adhesins.
• a combination of chitosan microspheres with different GlyRs and microspheres without Gly-Rs can also be used to improve the biding of H. pylori by the combination of non-specific H. pylori binding with specific H. pylori binding.
• Chitosan microspheres crosslinked with genipin and decorated with glycosylated receptors such as LeB (Fuca2Galp3[Fuca4]GlcNAc-R) and sLeX (NeuAca3Gaip4[Fuca3]GlcNAc-R) were produced.
• GlyR glycosylated receptors
• GlyR immobilization onto chitosan microspheres was carried out through the primary alcohol group of chitosan using the "click reaction" (corresponding to an azide-alkyne coupling) instead of the more reactive primary amine groups.
• the possibility to modify the primary alcohol group of chitosan powder using the "click reaction” was previously described by the inventors [27] using an azide terminated-PEG but not with carbohydrates such as glycan receptors.
• Chitosan microspheres were suspended in phthalic anhydride solution in 15 ml dimethylformamide (DMF) containing 5% (v/v) water and incubated for 15h at 75 °C under 200 rpm. The microspheres were afterwards rinsed with DMF and after with tetrahydrofuran (THF).
• DMF dimethylformamide
• THF tetrahydrofuran
• N-phthaloyl-chitosan microspheres were suspended in 30 mg/ml carbonyldiimidazole (CDI) solution in THF and incubated for 6h at 40°C under 200 rpm. After reaction, microspheres were rinsed with THF and then incubated in a propargylamine solution in THF for 15h at 25°C under 200 rpm. Finally the microspheres were rinsed with THF and dried.
• N-phthaloyl-chitosan Oprop-2-ynyl microspheres were added to N-phthaloyl-chitosan Oprop-2-ynyl microspheres: (1) lOmg/ml aqueous sodium ascorbate solution; (2) 10 mg/ml aqueous copper acetate solution in DMF and (3) aqueous solution of glycosylated receptor Lewis B (LeB) or sialyl-Lewis X (sLeX) . The mixture was incubated for 15h at 40°C under 200 rpm.
• Lewis B glycosylated receptor Lewis B
• sLeX sialyl-Lewis X
• Control chitosan microspheres (Alkyne-Microspheres) were prepared by undergoing all the processes but in this last step, instead of being incubated in a solution of GlyR, they were incubated in the solvent. The microspheres were rinsed with DMF and dried with ethanol.
• pylori strain 17.1 (BabA+/SabA-) was tested against chitosan microspheres without (Alkyne-Microspheres) and with different GlyRs (LeB-Microspheres and sLeX-Microspheres).
• Microspheres were able to attract and bind H. pylori specifically through its adhesins.
• LeB-Microspheres were able to attract and bind H. pylori through its specific adhesin BabA. Specific H. pylori adhesion was achieved since this H. pylori strain 17.1, that express BabA (specific to LeB receptors) adhered in much higher amounts to LeB-Microspheres than to sLeX-Microspheres and to microspheres without receptors (Alkyne-Microspheres) (see Figure 2).
• liver D Arnqvist A, Ogren J, Frick IM, Kersulyte D, Incecik ET, Berg DE, Covacci A, Engstrand L, Boren T, Helicobacter pylori adhesin binding fucosylated histo-blood group antigens revealed by retagging. Science. 1998, 279: 373-77; 8. Mahdavi, J., Sonden, B., Hurtig, M., Olfat, F.O., Forsberg, L., Roche, N., Angstrom, J., Larsson, T., Teneberg, S., Karlsson, K.-A., et al. (2002). Helicobacter pylori SabA Adhesin in Persistent Infection and Chronic Inflammation. Science 297, 573-578;
• Conway BR Drug delivery strategies for the treatment of Helicobacter pylori infections.
• Mi FL, Sung HW and Shyu SS Synthesis and Characterization of a Novel Chitosan- Based Network Prepared Using Naturally Occurring Crosslinker. J. Appl. Polym.2000;38:2804-2814.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Engineering & Computer Science (AREA)
• Animal Behavior & Ethology (AREA)
• Medicinal Chemistry (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Organic Chemistry (AREA)
• Nanotechnology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Oncology (AREA)
• Communicable Diseases (AREA)
• Immunology (AREA)
• Epidemiology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicinal Preparation (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=48428495

Family Applications (1)

Country Status (2)

Families Citing this family (2)

Family Cites Families (7)

• 2013
  • 2013-05-07 EP EP13722013.3A patent/EP2844301A2/de not_active Withdrawn
  • 2013-05-07 WO PCT/GB2013/051181 patent/WO2013164652A2/en active Application Filing

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events